KYMR - Kymera Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KYMR is currently covered by 16 analysts with an average price target of $65.58. This is a potential upside of $17.96 (37.72%) from yesterday's end of day stock price of $47.62.

Kymera Therapeutics's activity chart (see below) currently has 68 price targets and 91 ratings on display. The stock rating distribution of KYMR is 66.04% BUY and 33.96% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 64.23% with an average time for these price targets to be met of 241.93 days.

Highest price target for KYMR is $79, Lowest price target is $44, average price target is $57.07.

Most recent stock forecast was given by VIKRAM PUROHIT from MORGAN STANLEY on 03-Jun-2025. First documented stock forecast 15-Sep-2020.

Currently out of the existing stock ratings of KYMR, 35 are a BUY (66.04%), 18 are a HOLD (33.96%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$79

$31.38 (65.90%)

$34

5 days ago
(03-Jun-2025)

11/16 (68.75%)

$35.42 (81.28%)

191

Hold

$60

$12.38 (26.00%)

$41

5 days ago
(03-Jun-2025)

6/8 (75%)

$16.42 (37.68%)

218

Buy

$64

$16.38 (34.40%)

$47

5 days ago
(03-Jun-2025)

3/4 (75%)

$20.42 (46.86%)

403

Buy

$55

$7.38 (15.50%)

$56

19 days ago
(20-May-2025)

4/9 (44.44%)

$23.56 (74.94%)

240

Buy

$70

$22.38 (47.00%)

$74

26 days ago
(13-May-2025)

0/3 (0%)

$38.86 (124.79%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KYMR (Kymera Therapeutics) average time for price targets to be met?

On average it took 241.93 days on average for the stock forecasts to be realized with a an average price target met ratio 64.23

Which analyst has the current highest performing score on KYMR (Kymera Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the most public recommendations on KYMR (Kymera Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on KYMR

Which analyst is the currently most bullish on KYMR (Kymera Therapeutics)?

Vikram Purohit with highest potential upside - $31.38

Which analyst is the currently most reserved on KYMR (Kymera Therapeutics)?

Richard Law with lowest potential downside - -$10.62

Kymera Therapeutics in the News

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera Therapeutics, Inc. KYMR reported a first-quarter 2025 loss of 82 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, Kymera reported a loss of 69 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) The year-over-year deterioration was due...

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.87%. A quarter ago, it...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?